Case Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea

Simple item page
dc.contributor.authorFlorentino Abaga Ondo Ndoho
dc.contributor.authorLuca Fontana
dc.contributor.authorCandido Ondo Ondo Avomo
dc.contributor.authorLadislao Ekiri Ngomo Mikue
dc.contributor.authorDomitila Ñadang Fuga Eyemam
dc.contributor.authorMicaela Ayang Nguere
dc.contributor.authorIlda Elobe Mometolo
dc.contributor.authorRosalia Nazang Bibang Nzang
dc.contributor.authorDamaso Mitogo Nguema Maye
dc.contributor.authorYiliam Fundora Suarez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T19:36:07Z
dc.date.available2026-03-22T19:36:07Z
dc.date.issued2025
dc.description.abstractContrary to some reports and the recommended case definition for MVD, our patients presented with a rash but did not exhibit vomiting or diarrhea. Hemorrhagic signs were solely observed in the terminal stage, preceding demise. Despite the limited sample size, these findings emphasize the importance of tailoring the case definition to the specific outbreak. Further evidence on the efficacy and safety of therapeutics for MVD, including remdesivir, should be gathered through well-designed trials during future epidemic responses.
dc.identifier.doi10.1093/cid/ciaf208
dc.identifier.urihttps://doi.org/10.1093/cid/ciaf208
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/77012
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofClinical Infectious Diseases
dc.sourceMinisterio de Salud
dc.subjectMedicine
dc.subjectRash
dc.subjectOutbreak
dc.subjectDisease
dc.subjectNatural history
dc.subjectVomiting
dc.subjectPediatrics
dc.subjectAdverse effect
dc.subjectDiarrhea
dc.subjectInternal medicine
dc.titleCase Series of Patients With Laboratory-Confirmed Marburg Virus Disease in 2023 in Equatorial Guinea
dc.typearticle

Files

Collections

Artículo Científico Publicado